The 36-month beta value for BPMC is also noteworthy at 0.58. There are mixed opinions on the stock, with 5 analysts rating it as a “buy,” 4 rating it as “overweight,” 0 rating it as “hold,” and 0 rating it as “sell.”
The public float for BPMC is 62.20M, and at present, short sellers hold a 5.67% of that float. The average trading volume of BPMC on October 18, 2024 was 657.79K shares.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
BPMC) stock’s latest price update
The stock of Blueprint Medicines Corp (NASDAQ: BPMC) has decreased by -3.73 when compared to last closing price of 89.33.Despite this, the company has seen a loss of -1.12% in its stock price over the last five trading days. prnewswire.com reported 2024-10-16 that CAMBRIDGE, Mass., Oct. 16, 2024 /PRNewswire/ — Blueprint Medicines Corporation (NASDAQ: BPMC) today announced that it will host a live conference call and webcast at 8:00 a.m.
BPMC’s Market Performance
BPMC’s stock has fallen by -1.12% in the past week, with a monthly drop of -3.73% and a quarterly drop of -25.20%. The volatility ratio for the week is 2.97% while the volatility levels for the last 30 days are 3.14% for Blueprint Medicines Corp. The simple moving average for the past 20 days is -3.58% for BPMC’s stock, with a -9.26% simple moving average for the past 200 days.
Analysts’ Opinion of BPMC
Many brokerage firms have already submitted their reports for BPMC stocks, with Stephens repeating the rating for BPMC by listing it as a “Overweight.” The predicted price for BPMC in the upcoming period, according to Stephens is $140 based on the research report published on May 14, 2024 of the current year 2024.
Leerink Partners, on the other hand, stated in their research note that they expect to see BPMC reach a price target of $97, previously predicting the price at $50. The rating they have provided for BPMC stocks is “Market Perform” according to the report published on May 06th, 2024.
Oppenheimer gave a rating of “Outperform” to BPMC, setting the target price at $85 in the report published on October 27th of the previous year.
BPMC Trading at -5.04% from the 50-Day Moving Average
After a stumble in the market that brought BPMC to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -29.45% of loss for the given period.
Volatility was left at 3.14%, however, over the last 30 days, the volatility rate increased by 2.97%, as shares sank -5.43% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -5.34% lower at present.
During the last 5 trading sessions, BPMC fell by -1.12%, which changed the moving average for the period of 200-days by -5.57% in comparison to the 20-day moving average, which settled at $89.19. In addition, Blueprint Medicines Corp saw -6.76% in overturn over a single year, with a tendency to cut further losses.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BPMC starting from Namouni Fouad, who sale 3,633 shares at the price of $89.32 back on Oct 03 ’24. After this action, Namouni Fouad now owns 69,070 shares of Blueprint Medicines Corp, valued at $324,500 using the latest closing price.
Albers Jeffrey W., the Director of Blueprint Medicines Corp, sale 19,702 shares at $85.57 during a trade that took place back on Sep 09 ’24, which means that Albers Jeffrey W. is holding 157,557 shares at $1,685,891 based on the most recent closing price.
Stock Fundamentals for BPMC
Current profitability levels for the company are sitting at:
- -0.98 for the present operating margin
- 0.93 for the gross margin
The net margin for Blueprint Medicines Corp stands at -0.57. The total capital return value is set at -0.37. Equity return is now at value -65.09, with -17.79 for asset returns.
Based on Blueprint Medicines Corp (BPMC), the company’s capital structure generated 0.67 points at debt to capital in total, while cash flow to debt ratio is standing at -0.5. The debt to equity ratio resting at 2.08. The interest coverage ratio of the stock is -8.26.
Currently, EBITDA for the company is -474.61 million with net debt to EBITDA at -1.98. When we switch over and look at the enterprise to sales, we see a ratio of 16.91. The receivables turnover for the company is 4.27for trailing twelve months and the total asset turnover is 0.3. The liquidity ratio also appears to be rather interesting for investors as it stands at 3.71.
Conclusion
In summary, Blueprint Medicines Corp (BPMC) has had a bad performance as of late. Analysts have bullish opinions on the stock, with some viewing it as a “buy” and others as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
